What is Microbix Biosystems?
Founded in 1988 and headquartered in Mississauga, Ontario, Microbix Biosystems operates as a critical supplier to the global diagnostics industry. The company specializes in the development of proprietary biological materials, including high-quality antigens for immunoassays and laboratory quality assessment products (QAPs). These offerings are essential for clinical lab proficiency testing, assay development, and the validation of diagnostic workflows. Beyond its diagnostic portfolio, Microbix utilizes its robust biological infrastructure to advance proprietary technologies, most notably Kinlytic, a biologic thrombolytic drug designed for the treatment of blood clots. By bridging the gap between complex biological research and commercial-scale manufacturing, Microbix serves as a foundational pillar for clinical diagnostic accuracy and therapeutic development.
How much funding has Microbix Biosystems raised?
Microbix Biosystems has raised a total of $2.3M across 1 funding round:
Share Placement
$2.3M
Share Placement (2020): $2.3M, investors not publicly disclosed
Key Investors in Microbix Biosystems
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Microbix Biosystems?
With the recent influx of capital, Microbix is well-positioned to accelerate its strategic growth initiatives. The company is expected to focus on scaling its manufacturing capabilities for its core biological materials while simultaneously advancing the commercialization of its Kinlytic urokinase program. By strengthening its balance sheet, Microbix aims to enhance its competitive advantage in the diagnostics market, ensuring that its QAPs and antigen products remain the gold standard for clinical laboratories worldwide. Future developments will likely center on operational efficiency and the expansion of its proprietary technology pipeline, further cementing its role as a vital contributor to the global healthcare ecosystem.
See full Microbix Biosystems company page
